Dupilumab Therapy for EGIDs
Dupilumab Therapy for Refractory Eosinophilic Gastrointestinal Disorders in Children
Children's Hospital of Fudan University
20 participants
Jan 1, 2025
OBSERVATIONAL
Conditions
Summary
This is a single-center observational study to investigate the efficacy and tolerability of dupilumab in children with refractory eosinophilic gastrointestinal disorders.
Eligibility
Inclusion Criteria2
- Clinical diagnosis of Refractory Peptic Ulcers
- with Refractory Eosinophilic Gastrointestinal Disorders
Exclusion Criteria4
- with Active Helicobacter pylori infection at present.
- with Inflammatory bowel disease
- with Parasite infection
- with Cancer
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Dose: For patients with weight ≥ 15kg but \< 30kg, take 200mg each time, every two weeks; for those with weight ≤ 30kg but \< 60kg, take 300mg each time, every two weeks; for those with weight ≥ 60kg, take 300mg each time, once a week.
Dose: For patients with weight ≥ 15kg but \< 30kg, take 200mg each time, every two weeks; for those with weight ≤ 30kg but \< 60kg, take 300mg each time, every two weeks; for those with weight ≥ 60kg, take 300mg each time, once a week.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07257835